Roche gets NICE approval for breast cancer drug Kadcyla after years of battles
FiercePharma | June 15, 2017
Following four years of beating up on each other over the cost-benefit of Roche’s cutting-edge breast cancer drug Kadcyla, and heavy lobbying from cancer advocacy groups, the Swiss drugmaker and the U.K. drug cost watchdog have come to an accommodation.